MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
IDEXX Laboratories Total Assets 2011-2026 | IDXX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets IDEXX Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.29 B | 3.26 B | 2.75 B | 2.44 B | 2.29 B | 1.83 B | 1.54 B | 1.71 B | 1.53 B | 1.47 B | 1.38 B | 1.23 B | 1.1 B | 1.03 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.29 B | 1.03 B | 1.92 B |
Quarterly Total Assets IDEXX Laboratories
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.39 B | 3.33 B | 3.21 B | 3.29 B | 3.35 B | 3.41 B | 3.35 B | 3.26 B | 3.09 B | 2.87 B | 2.81 B | 2.75 B | 2.64 B | - | 2.59 B | 2.44 B | 2.39 B | 2.41 B | 2.33 B | 2.29 B | 2.29 B | 2.29 B | 2.29 B | 1.83 B | 1.83 B | 1.83 B | 1.83 B | 1.54 B | 1.54 B | 1.54 B | 1.54 B | 1.71 B | 1.71 B | 1.71 B | 1.71 B | 1.53 B | 1.53 B | 1.53 B | 1.53 B | 1.47 B | 1.47 B | 1.47 B | 1.47 B | 1.38 B | 1.38 B | 1.38 B | 1.38 B | 1.23 B | 1.23 B | 1.23 B | 1.23 B | 1.1 B | 1.1 B | 1.1 B | 1.1 B | 1.03 B | 1.03 B | 1.03 B | 1.03 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.41 B | 1.03 B | 1.96 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 22.96 | -0.56 % | $ 99.4 M |  Israel |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 237.64 | 1.12 % | $ 174 B | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 12.15 | -5.81 % | $ 345 M | Israel |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 23.25 | -0.66 % | $ 250 M |  China |
 |
DexCom
DXCM
|
6.26 B | $ 66.95 | -2.16 % | $ 25.8 B | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.59 | -0.94 % | $ 2.02 M | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 6.12 | - | $ 180 M | USA |
 |
IQVIA Holdings
IQV
|
26.9 B | $ 243.33 | 0.06 % | $ 44.1 B | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 39.59 | -0.76 % | $ 1.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Natera
NTRA
|
1.39 B | $ 234.65 | -2.05 % | $ 23.1 B | USA |
 |
CareDx, Inc
CDNA
|
467 M | $ 17.02 | -1.16 % | $ 915 M | USA |
 |
Celcuity
CELC
|
245 M | $ 107.43 | 2.63 % | $ 4.24 B | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Pacific Biosciences of California
PACB
|
1.75 B | $ 1.95 | -4.66 % | $ 495 M | USA |
 |
Anixa Biosciences
ANIX
|
21.6 M | $ 3.41 | -0.29 % | $ 109 K | USA |
 |
Exact Sciences Corporation
EXAS
|
5.93 B | $ 102.13 | 0.34 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 27.84 | -0.2 % | $ 842 M | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | $ 48.32 | -0.27 % | $ 10.8 B |  Niderland |
 |
RadNet
RDNT
|
3.29 B | $ 77.42 | -1.22 % | $ 5.65 B | USA |
 |
Guardant Health
GH
|
1.49 B | $ 110.18 | 1.32 % | $ 13.5 B | USA |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 141.01 | -3.31 % | $ 22.4 B | USA |
 |
Charles River Laboratories International
CRL
|
7.53 B | $ 220.64 | 2.38 % | $ 11.3 B | USA |
 |
Thermo Fisher Scientific
TMO
|
97.3 B | $ 620.69 | 2.34 % | $ 237 B | USA |
 |
Trinity Biotech plc
TRIB
|
103 M | $ 0.73 | -1.13 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
642 M | $ 35.58 | 2.42 % | $ 2.13 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 175.1 | -1.49 % | $ 19.4 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 5.46 | -2.15 % | $ 708 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 252.61 | -0.81 % | $ 21.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 183.13 | -2.7 % | $ 15.1 B | Irlanda |
 |
Lantheus Holdings
LNTH
|
1.98 B | $ 67.98 | 0.19 % | $ 4.7 B | USA |
 |
Agilent Technologies
A
|
10.7 B | $ 148.92 | 2.17 % | $ 45.3 B | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.75 | -4.84 % | $ 6.32 M | USA |
 |
Bioventus
BVS
|
811 M | $ 8.02 | 0.25 % | $ 502 M | USA |